Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Amphastar Pharmaceuticals Inc
Income from Continuing Operations
Amphastar Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
|
Income from Continuing Operations
$156.4m
|
CAGR 3-Years
361%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
35%
|
|
Johnson & Johnson
NYSE:JNJ
|
Income from Continuing Operations
$17.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Income from Continuing Operations
-$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Income from Continuing Operations
-$254m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Income from Continuing Operations
$6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
See Also
What is Amphastar Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
156.4m
USD
Based on the financial report for Mar 31, 2024, Amphastar Pharmaceuticals Inc's Income from Continuing Operations amounts to 156.4m USD.
What is Amphastar Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
35%
Over the last year, the Income from Continuing Operations growth was 66%. The average annual Income from Continuing Operations growth rates for Amphastar Pharmaceuticals Inc have been 361% over the past three years , and 35% over the past ten years .